Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Grunenthal
Deal Size : $83.2 million
Deal Type : Collaboration
Grünenthal, Kyowa Kirin International Enter Joint Venture Collaboration
Details : The joint venture collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral (fentanyl) and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3® for osteo...
Product Name : Abstral
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 02, 2023
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Grunenthal
Deal Size : $83.2 million
Deal Type : Collaboration
Reset All
